← All Futuretech Ii Acquisition CORP filings

Futuretech Ii Acquisition CORP DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

OTC.Pink
FTII
Futuretech Ii Acquisition CORP
DEF: FutureTech II Acquisition Corp. Seeks Shareholder Vote to Extend Business Combination Deadline
FutureTech II Acquisition Corp. is holding a special meeting on August 13, 2026, to vote on extending its deadline to complete a business combination by nine months to May 18, 2027.
OTC.Pink
FTII
Futuretech Ii Acquisition CORP
DEF 14A: FutureTech II Seeks SPAC Extension to Aug 2026
FutureTech II Acquisition Corp. seeks stockholder approval to extend its business combination deadline to August 18, 2026, to complete its merger with Longevity Biomedical, Inc.
OTC.Pink
FTII
Futuretech Ii Acquisition CORP
DEFA14A: FutureTech II Acquisition Corp. Amends Proxy, Removes Extension Payment Cap and Postpones Special Meeting
FutureTech II Acquisition Corp. has amended its proxy statement to remove the $50,000 cap on extension payments and has postponed its special meeting to November 18, 2024.
OTC.Pink
FTII
Futuretech Ii Acquisition CORP
DEFR14A: FutureTech II Acquisition Corp. Seeks Extension and Founder Share Amendment to Facilitate Business Combination
FutureTech II Acquisition Corp. is seeking stockholder approval to extend the deadline for completing a business combination and to amend the charter to allow for earlier conversion of founder shares to maintain Nasdaq compliance.
OTC.Pink
FTII
Futuretech Ii Acquisition CORP
DEF 14A: FutureTech II Acquisition Corp. Seeks Extension and Founder Share Amendment to Facilitate Longevity Biomedical Merger, Avert Nasdaq Delisting
FutureTech II Acquisition Corp. is seeking stockholder approval to extend its business combination deadline and amend founder share conversion terms to maintain its Nasdaq listing and proceed with its merger with Longevity Biomedical, Inc.